Veloxis Pharmaceuticals settles $46 million qui tam case over alleged kickbacks
Executive summary: Veloxis Pharmaceuticals admitted to providing illegal kickbacks and agreed to pay about $46 million in fines and penalties under a deferred prosecution agreement following a qui tam action. The settlement demonstrates active DOJ enforcement of anti‑kickback laws, imposes a significant financial penalty on the company, and may prompt stricter compliance programs across the pharma industry.
Who is involved: Veloxis Pharmaceuticals, the whistleblower law firms Kleiman Rajaram and Phillips & Cohen, and the U.S. Department of Justice.
Likely next: Veloxis must implement and monitor a compliance regimen over the term of the agreement, while regulators may continue to oversee adherence and shareholders could pursue related litigation.
On August 15, 2026, Veloxis Pharmaceuticals entered into a deferred prosecution agreement with U.S. authorities after admitting to providing illegal kickbacks to healthcare providers. The settlement, stemming from a qui tam lawsuit filed by law firms Kleiman Rajaram and Phillips & Cohen, requires the company to pay approximately $46 million in criminal fines and civil penalties. The case underscores continued federal enforcement of the Anti‑Kickback Statute in the pharmaceutical sector.
Timeline
- — Kleiman Rajaram and Phillips & Cohen Announce Successful $46 Million Qui Tam Action Against Veloxis Pharmaceuticals (PR Newswire)
Analysis — what this means
Sectors affected
- Pharmaceutical manufacturing
- Healthcare compliance
Sources
- Kleiman Rajaram and Phillips & Cohen Announce Successful $46 Million Qui Tam Action Against Veloxis Pharmaceuticals — PR Newswire
Related cases
- Shihezi launches International Week to position Xinjiang as a global hub for trade and cultural exchange
- The shooting at a Swiss rave party highlights security risks for large gatherings, potentially boosting demand for private security and event insurance
- Jukebox’s free 4x AI upscaling raises the bar for background removal tools
- iScreen launches interactive digital pet feature for iPhone home screen customization
- Pharmacy leaders set workforce readiness and funding as priorities for primary care integration
- Rare Cannabinoid Company releases educational guide to boost consumer awareness of minor cannabinoids in the hemp wellness market